[296 Pages Report] Pharmaceutical intermediates are used as raw materials during the manufacture of bulk drugs. Leading biopharmaceutical and pharmaceutical manufacturing companies are focusing on improving their product footprint globally. These companies are focusing on strengthening their product reach in different countries across the world through various distribution channels. Growth outlook therefore remains positive for pharmaceutical intermediates market as companies continue focusing on enhancing the capacities of their manufacturing plants in various countries of the world.
In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights about key factors fuelling demand for pharmaceutical intermediates. The report tracks the global sales of pharmaceutical intermediates in 20+ high-growth markets, along with analyzing the impact COVID-19 has on the pharmaceutical industry in general and the market in particular.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The rapidly increasing prevalence of chronic diseases and growth of the aging population across the world are among factors that are expected to increase the need for drug formulations for the prevention of chronic diseases. For instance, as per the International Diabetes Federation Diabetes, The global diabetes prevalence in 2019 is estimated to be 9.3% (463 million people), rising to 10.2% (578 million) by 2030, and the number is rising rapidly. Pharmaceutical drugs have remained key to management of chronic diseases and other diseases.
For instance, according to the World Health Organization (WHO), the prevalence of chronic diseases is expected to increase by 57.0% by 2020, which indicates that a significant percentage of population is suffering from chronic diseases. According to FMI’s analysis, pharmaceutical intermediates sales have grown at 3.7% CAGR between 2015 and 2019.
Various small- and medium-scale companies are also focusing on enhancing their production capacity, which is another factor that is expected to fuel growth of the pharmaceutical intermediates demand. Hence demand for pharmaceutical intermediate is increasing and sales are set to grow significantly through 2030.
Moreover, major pharma companies are increasingly relying on contract manufacturing organizations for the manufacturing of pharmaceutical intermediates and final formulations. These companies are focusing on enhancing the capacities of their manufacturing plants in various countries of the world, such as India and China, where the cost of production is comparatively lower. These developments present a positive outlook for growth. FMI expects global pharmaceutical intermediates market to grow at 4.3% CAGR through 2030.
The rapidly increasing prevalence of chronic diseases and rising the aging population across the world are among chief factors that are expected to increase the need for drug formulations for the prevention of various diseases. According to the World Health Organization (WHO), population comprising of people aged 60 years and above is expected to total 2 billion by 2050. Also, according to the WHO, diabetes continues to be a major cause of kidney failure, stroke, heart attacks, and other chronic ailments.
Moreover, the global increase in aging population is expected to increase the demand for drugs for the management of age-related chronic conditions, which is also expected to boost the pharmaceutical intermediates market. Outbreak of pandemics such as COVID-19, H1N1, Ebola, and others are increasing the requirement of different pharmaceutical intermediates as well as APIs, which signifies the growth potential for the pharmaceutical intermediates.
As a matter of fact the demand for generic and branded products is on rise due to the prevalence of various chronic diseases and increasing aging population, which in turn, is expected to create significant revenue generation opportunities for the pharmaceutical intermediates market. Manufacturers of API are also trying to enhance their production due to the high global demand owing to a shortage of various generic drugs. Increasing reach of various pharma players in the developing countries is also expected to boost the demand for pharmaceutical intermediates.
The WHO has launched Integrated Chronic Disease Prevention and Control Programme (ICP), which is one of the leading technical programme within the Department of Chronic Diseases and Health Promotion (CHP). Such initiatives are expected to support overall expansion of the market.
Principal Consultant
Due to rapid development happening in the biotechnology and life science field, demand registered in the market has been significantly rising. Moreover, a wide array of application and increasing adoption of pharmaceutical intermediates in the field of clinical research are creating lucrative prospects for growth. Manufacturers in the biotechnology and pharmaceutical sectors are focusing on drug development activities along with research institutes, especially in the wake of COVID-19.
In fact the ongoing pandemic has been reshaping the pharmaceutical supply chain. Chemical and Engineering news had reported in April 2020, that Director of the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research, Janet Woodcock, has shared with a House of Representatives subcommittee that the number of facilities in China supplies active pharmaceutical ingredients has more than doubled itself since 2010. This is presents positive outlook for the market.
FMI has projected East Asia hold more than thirty percent markets share through the course of the forecast period. Growth within the region is likely to be spearheaded by China. As per FMI, the China pharmaceutical intermediates market is estimated to surpass US$ 7 Bn in 2021, exhibiting a CAGR of 6% through 2030.
China remains one of the largest markets for pharmaceutical industries in the world. The China Government has been supporting research and development initiatives by various pharmaceutical companies with special attention to the biotechnology sector. Moreover, government taking initiative to support for foreign investment in R&D. providing better access of medicine to people is the prime concern for the Chinese Government.
Pharmaceuticals account for a substantial part of the current China health care budget. According to China.org.cn, China’s pharmaceutical market is expected to reach US$161.8 bn by 2023. Also as per, the Information Technology and Innovation Foundation, the 2017 Biopharmaceutical Competitiveness and Investment Survey has ranked China 20th among 27 nations on a variety of measures undertaken for biopharma innovation.
Chinese pharmaceutical manufacturers have until recently concentrated on the production of basic chemicals, intermediates and APIs. In short period of time, China has become the leading global supplier of APIs in terms of volume. As per the WHO report, in 2017 “Total revenues from sales of pharmaceuticals in China are substantially in excess of 100 billion US$, making China the second-largest pharmaceutical market in the world”
Leading pharmaceutical companies have announced their intentions to invest in manufacturing facilities due to various reasons such as enhancing the production capacity, reducing corporate tax rate in the U.S., among others. The recent tax reforms in the country which include reduction of the corporate tax rate, have encouraged various large biopharmaceutical and pharmaceutical companies to invest in production facilities.
For example, in July 2018, Pfizer announced its plan to invest around US$ 465.0 million to build a sterile injectable plant in Portage, Michigan. This step is a part of its announcement that it had made earlier in 2018 about its plans to invest around US$ 5.0 billion in a U.S.-based capital project due to the recent corporate tax reforms in the country. Similarly, Amgen announced a 5-year capital investment of approximately US$ 3.5 billion in the U.S. and later in July 2018, it announced a new US$ 300 million plant in Greenwich, Rhode Island campus. Eli Lilly announced an investment of US$ 72.0 million for an insulin manufacturing project in 2018.
Currently, India is one of the top five global manufacturers of pharmaceutical intermediates. The production of pharmaceutical intermediates has continued to grow with an increasing number of multinational companies in India to meet their pharmaceutical intermediates supply needs. In addition, India has the largest number of United States Food & Drug Administration -approved production companies outside the USA.
Every year Indian companies file significant number of drug master filings (DMF). Moreover, increasing production of APIs has led to increase demand for pharmaceutical intermediates. In India chemical manufacturers have the R&D capabilities and technical expertise to produce high-quality, complex, and niche intermediates. The key drugs driving sales and hence, the production of pharmaceutical intermediates, have been anti-infective and antibiotics, anti-inflammatory drugs, central nervous system drugs, cardiovascular system drugs, anti-diabetics
Japan is the 3rd largest pharma industry in the world. The Japanese government has gone as far as to increase investment in the generic drug market. According to the International Society for Pharmaceutical Engineering, the use of generic drugs increased to 65.8% in 2017 from 39.9% in 2011.
The total annual pharmaceutical spending accounted for 18.3% of health spending in 2017, as per the Organization for Economic Co-operation and Development (OCED). Moreover, Government of Japan’s national insurance scheme has been favoring growth of the overall pharmaceutical sector. Increase burden of aging population and wide access to healthcare are the chief driving factors of pharmaceutical intermediates market.
While China and the U.S. will continue leading, growth in Germany is expected to happen at an accelerated pace. As per FMI, presence of pharmaceutical intermediate companies in Germany is more. Some prominent players in pharmaceutical intermediate such as Chiracon GmbH, Midas Pharma GmbH, BASF SE are present in Germany which creates significant revenue. Moreover, large number of domestic players also available in Germany which create surge in pharmaceutical intermediate production in Germany.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The bulk drug intermediates segment will continue accounting for over 60% the global share among products through the forecast period. According to FMI, the segment is expected to hold a more than 60% of the market, in terms of product type, by the end of 2030. Bulk drug intermediates segment going to show significant growth in India. For promotion of Bulk Drug Parks, PM Narendra Modi has approved schemes to promote Bulk Drug Parks. Government provide financial implication of US$ 409 Mn for next five years For 3 Bulk Drug Parks. Moreover, Bulk drug intermediates are mostly used in drug development process.
Generic drug intermediates by category type holds more than 60% of the overall share through the forecast period, generic drug intermediates continue to account for increasing demand. Rising growth of generic drug intermediates in countries such as Japan, China, and India will continue aiding expansion in the segment. In Japan, government is targeting 80% generic penetration by 2020 and start gradual reduction in use of branded products.
Moreover, generic drug manufacturers in India are integral to the expansion of the pharmaceutical industry and hold strong supply chain globally. In addition to this India is the source of sixty thousand generic brands across sixty therapeutic categories and manufactures more than five hundred APIs.
Accounting for over 30% of the global market, analgesics will account for maximum application of pharmaceutical intermediates through the course of the forecast period. Analgesics are increasingly used for providing short-term or long-term relief for severe pain. Expansion within this category will be driven by the rising incidence of chronic ailments such as cancer, arthritis, cardiovascular diseases, and others.
According to the arthritis.org, arthritis affects at least one in four adults in the U.S. Meanwhile, the WHO says that the prevalence of arthritis varies between 0.3% and 1% in developed countries. With incidence of chronic ailments forecast to rise further, the demand for analgesics is expected to get stronger in the coming years.
FMI has forecast CMOs/ CROs to account for the leading market share through the course of the forecast period. Growth witnessed in CMOs/ CROs industries in the last few years has been resulting in high demand for pharmaceutical intermediates. Contract research organizations (CROs) are more popular because they offer cost-effective solutions to firms seeking to produce medicines and large markets, alike.
Contract manufacturing organizations (CMOs) serve various organizations within the pharmaceutical industry with contractual services. Rise in automation in the CMO industry to offer more personalized experience has been enabling growth in the segment.
Some of the leading companies operating in the market are Cambrex Corporation, BASF SE, Aceto Crporation, Interchem, Cambrex Corporation, Arkema Inc. Major Manufacturers are focusing on development of intermediates by offering wide range of pharmaceutical intermediates. Moreover, major players in pharmaceutical intermediates market are focus on enhancing their global and regional presence through acquisition and expansion. For instance, On February 2019, ACETO announced sale of its chemicals business assets to New Mountain Capital for $338 million. On July 2017, Lianhetech announced the acquisition of Fine Industries Limited including its subsidiaries Fine Organics Ltd. and Fine Environmental Services Ltd.
Some of the leading companies operating in the market are:
*The list is not exhaustive, and only for representational purposes. Full competitive intelligence with SWOT analysis available in the report.
| Attribute | Details |
|---|---|
| Pharmaceutical Intermediates Market - Forecast Period | 2020 to 2030 |
| Pharmaceutical Intermediates Market - Historical Data Available for | 2016 to 2019 |
| Pharmaceutical Intermediates Market - Market Analysis | USD Million for value and Units for Volume |
| Pharmaceutical Intermediates Market - Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania Middle East & Africa |
| Pharmaceutical Intermediates Market - Key Countries Covered | USA, Canada, Germany, UK, France, Italy, Spain, BENELUX, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, South Africa |
| Pharmaceutical Intermediates Market - Key Segments Covered | Product Type, Category, Application, End User and Region |
| Pharmaceutical Intermediates Market - Key Companies Profiled | Cambrex Corporation; BASF SE.; Aceto Crporation; Interchem.; Arkema Inc.; Chiracon GmbH.; Midas Pharma GmbH.; Chemcon Specialty Chemical Pvt. Ltd..; Dextra Laboratories Limited; Pfizer; Codexis, Inc; Sanofi; Dishman Group; Dextra Laboratories Limited. |
| Pharmaceutical Intermediates Market - Report Coverage | Market Forecast, company share analysis, competition intelligence, DROT analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
China currently leads the global market for pharmaceutical intermediates. Sales in China will be over 40% of total demand throughout the forecast period.
Bulk drug intermediates are highly sought-after in every market. The demand for bulk drug intermediates are expected to remain high in the near future, especially due to growing usage in drug development.
Pharmaceutical intermediates are mostly used in analgesics drug development.
Some of the leading companies offering pharmaceutical intermediates are Cambrex Corporation, BASF SE, Aceto Crporation, Interchem, Arkema Inc., among others.
The World Health Organization has identified chronic disease as one of the major death causing factor around the world. It also estimated that more than 35 million people had died due to chronic disease globally.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Market Context 4.1. Product Adoption / Usage Analysis 4.2. Promotional Strategies by Key Players 4.3. Regulatory Scenario 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Per Capita Healthcare Expenditure Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Increasing prevalence of Chronic Disorders 5.2.2. Increasing Investments in Pharmaceutical Intermediates manufacturing 5.2.3. Growing aging population of the world 5.3. Value Chain 5.4. Market Dynamics 5.4.1. Drivers 5.4.2. Restraints 5.4.3. Opportunity Analysis 6. COVID19 Crisis Impact Analysis 6.1. Current COVID-19 Statistics and Probable Future Impact 6.2. Current GDP Projection and Probable Impact 6.3. Current Economic Projection as compared to 2008 financial analysis 6.4. COVID19 and Impact Analysis 6.4.1. Revenue By Product 6.4.2. Revenue By Country 6.5. 2020 Market Scenario 6.6. Quarter by Quarter Forecast 6.7. Projected recovery Quarter 6.8. Recovery Scenario - Short term, Midterm and Long Term Impact 7. Global Pharmaceutical Intermediates Market Value (US$ Mn) Analysis 2015-2019 and Forecast, 2020-2030 7.1. Historical Market Value (US$ Mn) Analysis, 2015-2019 7.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Pharmaceutical Intermediates Market Analysis 2015-2019 and Forecast 2020-2030, by Product Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2015-2019 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product Type, 2020-2030 8.3.1. Chemical Intermediates 8.3.2. Bulk Drug Intermediates 8.3.2.1. Chiral Intermediates 8.3.2.2. Achiral Intermediates 8.3.3. Custom Intermediates 8.4. Market Attractiveness Analysis By Product Type 9. Global Pharmaceutical Intermediates Market Analysis 2015-2019 and Forecast 2020-2030, by Category 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2015-2019 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Category, 2020-2030 9.3.1. Branded Drug Intermediates 9.3.2. Generic Drug Intermediates 9.4. Market Attractiveness Analysis By Category 10. Global Pharmaceutical Intermediates Market Analysis 2015-2019 and Forecast 2020-2030, by Application 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2015-2019 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Category, 2020-2030 10.3.1. Analgesics 10.3.2. Anti-inflammatory Drug 10.3.3. Cardiovascular Drugs 10.3.4. Anti-diabetic Drugs 10.3.5. Antimicrobial Drugs 10.3.6. Anti-cancer Drugs 10.3.7. Others 10.4. Market Attractiveness Analysis By Category 11. Global Pharmaceutical Intermediates Market Analysis 2015-2019 and Forecast 2020-2030, by End User 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) Analysis By End User, 2015-2019 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2020-2030 11.3.1. Biotech and Pharma Companies 11.3.2. Research Laboratory 11.3.3. CMOs/CROs 11.4. Market Attractiveness Analysis By End User 12. Global Pharmaceutical Intermediates Market Analysis 2015-2019 and Forecast 2020-2030, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2015 - 2019 12.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2020 - 2030 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Pharmaceutical Intermediates Market Analysis 2015-2019 and Forecast 2020-2030 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2030 13.3.1. By Country 13.3.1.1. U.S. 13.3.1.2. Canada 13.3.2. By Product Type 13.3.3. Category 13.3.4. Application 13.3.5. By End User 13.4. Market Attractiveness Analysis 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 14. Latin America Pharmaceutical Intermediates Market Analysis 2015-2019 and Forecast 2020-2030 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2030 14.3.1. By Country 14.3.1.1. Brazil 14.3.1.2. Mexico 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Product Type 14.3.3. Category 14.3.4. Application 14.3.5. By End User 14.4. Market Attractiveness Analysis 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 15. Europe Pharmaceutical Intermediates Market Analysis 2015-2019 and Forecast 2020-2030 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2030 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. U.K. 15.3.1.5. Spain 15.3.1.6. BENELUX 15.3.1.7. Russia 15.3.1.8. Rest of Europe 15.3.2. By Product Type 15.3.3. Category 15.3.4. Application 15.3.5. By End User 15.4. Market Attractiveness Analysis 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 16. South Asia Pharmaceutical Intermediates Market Analysis 2015-2019 and Forecast 2020-2030 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2030 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Thailand 16.3.1.3. Indonesia 16.3.1.4. Malaysia 16.3.1.5. Rest of South Asia 16.3.2. By Product Type 16.3.3. Category 16.3.4. Application 16.3.5. By End User 16.4. Market Attractiveness Analysis 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 17. East Asia Pharmaceutical Intermediates Market Analysis 2015-2019 and Forecast 2020-2030 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2030 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.2. By Product Type 17.3.3. Category 17.3.4. Application 17.3.5. By End User 17.4. Market Attractiveness Analysis 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 18. Oceania Pharmaceutical Intermediates Market Analysis 2015-2019 and Forecast 2020-2030 18.1. Introduction 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2030 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Product Type 18.3.3. Category 18.3.4. Application 18.3.5. By End User 18.4. Market Attractiveness Analysis 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 19. Middle East and Africa Pharmaceutical Intermediates Market Analysis 2015-2019 and Forecast 2020-2030 19.1. Introduction 19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2019 19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2030 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. Turkey 19.3.1.3. South Africa 19.3.1.4. Rest of Middle East and Africa 19.3.2. By Product Type 19.3.3. Category 19.3.4. Application 19.3.5. By End User 19.4. Market Attractiveness Analysis 19.5. Key Market Participants - Intensity Mapping 19.6. Drivers and Restraints - Impact Analysis 20. Key and Emerging Countries Pharmaceutical Intermediates Market Analysis 2015-2019 and Forecast 2020-2030 20.1. Introduction 20.1.1. Market Value Proportion Analysis, By Key Countries 20.1.2. Global Vs. Country Growth Comparison 20.2. U.S. Pharmaceutical Intermediates Market Analysis 20.2.1. By Product Type 20.2.2. Category 20.2.3. Application 20.2.4. By End User 20.3. Canada Pharmaceutical Intermediates Market Analysis 20.3.1. By Product Type 20.3.2. Category 20.3.3. Application 20.3.4. By End User 20.4. Mexico Pharmaceutical Intermediates Market Analysis 20.4.1. By Product Type 20.4.2. Category 20.4.3. Application 20.4.4. By End User 20.5. Brazil Pharmaceutical Intermediates Market Analysis 20.5.1. By Product Type 20.5.2. Category 20.5.3. Application 20.5.4. By End User 20.6. U.K. Pharmaceutical Intermediates Market Analysis 20.6.1. By Product Type 20.6.2. Category 20.6.3. Application 20.6.4. By End User 20.7. Germany Pharmaceutical Intermediates Market Analysis 20.7.1. By Product Type 20.7.2. Category 20.7.3. Application 20.7.4. By End User 20.8. France Pharmaceutical Intermediates Market Analysis 20.8.1. By Product Type 20.8.2. Category 20.8.3. Application 20.8.4. By End User 20.9. Italy Pharmaceutical Intermediates Market Analysis 20.9.1. By Product Type 20.9.2. Category 20.9.3. Application 20.9.4. By End User 20.10. BENELUX Pharmaceutical Intermediates Market Analysis 20.10.1. By Product Type 20.10.2. Category 20.10.3. Application 20.10.4. By End User 20.11. Russia Pharmaceutical Intermediates Market Analysis 20.11.1. By Product Type 20.11.2. Category 20.11.3. Application 20.11.4. By End User 20.12. China Pharmaceutical Intermediates Market Analysis 20.12.1. By Product Type 20.12.2. Category 20.12.3. Application 20.12.4. By End User 20.13. Japan Pharmaceutical Intermediates Market Analysis 20.13.1. By Product Type 20.13.2. Category 20.13.3. Application 20.13.4. By End User 20.14. South Korea Pharmaceutical Intermediates Market Analysis 20.14.1. By Product Type 20.14.2. Category 20.14.3. Application 20.14.4. By End User 20.15. India Pharmaceutical Intermediates Market Analysis 20.15.1. By Product Type 20.15.2. Category 20.15.3. Application 20.15.4. By End User 20.16. Australia Pharmaceutical Intermediates Market Analysis 20.16.1. By Product Type 20.16.2. Category 20.16.3. Application 20.16.4. By End User 20.17. New Zealand Pharmaceutical Intermediates Market Analysis 20.17.1. By Product Type 20.17.2. Category 20.17.3. Application 20.17.4. By End User 20.18. GCC Countries Pharmaceutical Intermediates Market Analysis 20.18.1. By Product Type 20.18.2. Category 20.18.3. Application 20.18.4. By End User 20.19. Turkey Pharmaceutical Intermediates Market Analysis 20.19.1. By Product Type 20.19.2. Category 20.19.3. Application 20.19.4. By End User 20.20. South Africa Pharmaceutical Intermediates Market Analysis 20.20.1. By Product Type 20.20.2. Category 20.20.3. Application 20.20.4. By End User 21. Market Structure Analysis 21.1. Market Analysis by Tier of Companies 21.2. Market Concentration 21.3. Market Share Analysis of Top Players 21.4. Market Presence Analysis 21.4.1. By Regional footprint of Players 21.4.2. Product foot print by Players 21.4.3. Channel Foot Print by Players 22. Competition Analysis 22.1. Competition Dashboard 22.2. Competition Deep Dive 22.2.1. Chiracon GmbH 22.2.1.1. Overview 22.2.1.2. Product Portfolio 22.2.1.3. Profitability by Market Segments (Product/End User/Region) 22.2.1.4. Sales Footprint 22.2.1.5. Strategy Overview 22.2.1.5.1. Marketing Strategy 22.2.1.5.2. Product Strategy 22.2.1.5.3. Channel Strategy 22.2.2. Aceto Corporation 22.2.2.1. Overview 22.2.2.2. Product Portfolio 22.2.2.3. Profitability by Market Segments (Product/End User/Region) 22.2.2.4. Sales Footprint 22.2.2.5. Strategy Overview 22.2.2.5.1. Marketing Strategy 22.2.2.5.2. Product Strategy 22.2.2.5.3. Channel Strategy 22.2.3. Midas Pharma GmbH 22.2.3.1. Overview 22.2.3.2. Product Portfolio 22.2.3.3. Profitability by Market Segments (Product/End User/Region) 22.2.3.4. Sales Footprint 22.2.3.5. Strategy Overview 22.2.3.5.1. Marketing Strategy 22.2.3.5.2. Product Strategy 22.2.3.5.3. Channel Strategy 22.2.4. Codexis 22.2.4.1. Overview 22.2.4.2. Product Portfolio 22.2.4.3. Profitability by Market Segments (Product/End User/Region) 22.2.4.4. Sales Footprint 22.2.4.5. Strategy Overview 22.2.4.5.1. Marketing Strategy 22.2.4.5.2. Product Strategy 22.2.4.5.3. Channel Strategy 22.2.5. Lianhe Chemical Technology Co., Ltd 22.2.5.1. Overview 22.2.5.2. Product Portfolio 22.2.5.3. Profitability by Market Segments (Product/End User/Region) 22.2.5.4. Sales Footprint 22.2.5.5. Strategy Overview 22.2.5.5.1. Marketing Strategy 22.2.5.5.2. Product Strategy 22.2.5.5.3. Channel Strategy 22.2.6. BASF SE 22.2.6.1. Overview 22.2.6.2. Product Portfolio 22.2.6.3. Profitability by Market Segments (Product/End User/Region) 22.2.6.4. Sales Footprint 22.2.6.5. Strategy Overview 22.2.6.5.1. Marketing Strategy 22.2.6.5.2. Product Strategy 22.2.6.5.3. Channel Strategy 22.2.7. Vertellus Holdings LLC 22.2.7.1. Overview 22.2.7.2. Product Portfolio 22.2.7.3. Profitability by Market Segments (Product/End User/Region) 22.2.7.4. Sales Footprint 22.2.7.5. Strategy Overview 22.2.7.5.1. Marketing Strategy 22.2.7.5.2. Product Strategy 22.2.7.5.3. Channel Strategy 22.2.8. Sanofi S.A. 22.2.8.1. Overview 22.2.8.2. Product Portfolio 22.2.8.3. Profitability by Market Segments (Product/End User/Region) 22.2.8.4. Sales Footprint 22.2.8.5. Strategy Overview 22.2.8.5.1. Marketing Strategy 22.2.8.5.2. Product Strategy 22.2.8.5.3. Channel Strategy 22.2.9. A. R. Life Sciences Private Limited 22.2.9.1. Overview 22.2.9.2. Product Portfolio 22.2.9.3. Profitability by Market Segments (Product/End User/Region) 22.2.9.4. Sales Footprint 22.2.9.5. Strategy Overview 22.2.9.5.1. Marketing Strategy 22.2.9.5.2. Product Strategy 22.2.9.5.3. Channel Strategy 22.2.10. Dishman Group 22.2.10.1. Overview 22.2.10.2. Product Portfolio 22.2.10.3. Profitability by Market Segments (Product/End User/Region) 22.2.10.4. Sales Footprint 22.2.10.5. Strategy Overview 22.2.10.5.1. Marketing Strategy 22.2.10.5.2. Product Strategy 22.2.10.5.3. Channel Strategy 22.2.11. Chemcon Speciality Chemicals Pvt. Ltd 22.2.11.1. Overview 22.2.11.2. Product Portfolio 22.2.11.3. Profitability by Market Segments (Product/End User/Region) 22.2.11.4. Sales Footprint 22.2.11.5. Strategy Overview 22.2.11.5.1. Marketing Strategy 22.2.11.5.2. Product Strategy 22.2.11.5.3. Channel Strategy 22.2.12. Dextra Laboratories Ltd 22.2.12.1. Overview 22.2.12.2. Product Portfolio 22.2.12.3. Profitability by Market Segments (Product/End User/Region) 22.2.12.4. Sales Footprint 22.2.12.5. Strategy Overview 22.2.12.5.1. Marketing Strategy 22.2.12.5.2. Product Strategy 22.2.12.5.3. Channel Strategy 22.2.13. ZCL Chemicals Ltd 22.2.13.1. Overview 22.2.13.2. Product Portfolio 22.2.13.3. Profitability by Market Segments (Product/End User/Region) 22.2.13.4. Sales Footprint 22.2.13.5. Strategy Overview 22.2.13.5.1. Marketing Strategy 22.2.13.5.2. Product Strategy 22.2.13.5.3. Channel Strategy 22.2.14. Eastar Industries 22.2.14.1. Overview 22.2.14.2. Product Portfolio 22.2.14.3. Profitability by Market Segments (Product/End User/Region) 22.2.14.4. Sales Footprint 22.2.14.5. Strategy Overview 22.2.14.5.1. Marketing Strategy 22.2.14.5.2. Product Strategy 22.2.14.5.3. Channel Strategy 22.2.15. Pfizer Inc. 22.2.15.1. Overview 22.2.15.2. Product Portfolio 22.2.15.3. Profitability by Market Segments (Product/End User/Region) 22.2.15.4. Sales Footprint 22.2.15.5. Strategy Overview 22.2.15.5.1. Marketing Strategy 22.2.15.5.2. Product Strategy 22.2.15.5.3. Channel Strategy 22.2.16. Bristol-Myers Squibb Company 22.2.16.1. Overview 22.2.16.2. Product Portfolio 22.2.16.3. Profitability by Market Segments (Product/End User/Region) 22.2.16.4. Sales Footprint 22.2.16.5. Strategy Overview 22.2.16.5.1. Marketing Strategy 22.2.16.5.2. Product Strategy 22.2.16.5.3. Channel Strategy 22.2.17. Arkema Group 22.2.17.1. Overview 22.2.17.2. Product Portfolio 22.2.17.3. Profitability by Market Segments (Product/End User/Region) 22.2.17.4. Sales Footprint 22.2.17.5. Strategy Overview 22.2.17.5.1. Marketing Strategy 22.2.17.5.2. Product Strategy 22.2.17.5.3. Channel Strategy 22.2.18. Interchem 22.2.18.1. Overview 22.2.18.2. Product Portfolio 22.2.18.3. Profitability by Market Segments (Product/End User/Region) 22.2.18.4. Sales Footprint 22.2.18.5. Strategy Overview 22.2.18.5.1. Marketing Strategy 22.2.18.5.2. Product Strategy 22.2.18.5.3. Channel Strategy 22.2.19. Cambrex Corporation 22.2.19.1. Overview 22.2.19.2. Product Portfolio 22.2.19.3. Profitability by Market Segments (Product/End User/Region) 22.2.19.4. Sales Footprint 22.2.19.5. Strategy Overview 22.2.19.5.1. Marketing Strategy 22.2.19.5.2. Product Strategy 22.2.19.5.3. Channel Strategy 23. Assumptions and Acronyms Used 24. Research Methodology
Explore Healthcare Insights
View Reports
Pharmaceutical Intermediates Market
